SCHEMBL7089912

SCHEMBL7089912

Cc1ccccc1C(=O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.68
ALDH1A1 P00352 3/20 0.64
SERPINE1 P05121 6/20 0.63
KDM4E B2RXH2 1/20 0.61
HSD17B10 Q99714 1/20 0.61
PPARG P37231 1/20 0.61
PPARA Q07869 1/20 0.61
AKR1C4 P17516 1/20 0.59
AKR1C3 P42330 1/20 0.59
AKR1C2 P52895 1/20 0.59
AKR1C1 Q04828 1/20 0.59
LMNA P02545 2/20 0.58
MAPT P10636 2/20 0.58
TP53 P04637 1/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28472225 0.86 KCNMA1 (0.65) KCNMA1ALDH1A1SERPINE1LMNAMAPT
SCHEMBL27851450 0.85 SERPINE1 (0.70) KCNMA1SERPINE1KDM4EHSD17B10PPARG
SCHEMBL12225787 0.85 KCNMA1 (0.72) KCNMA1ALDH1A1KDM4EPPARGPPARA
SCHEMBL27970823 0.85 HPGD (0.64) KCNMA1ALDH1A1KDM4EHSD17B10LMNA
SCHEMBL7088697 0.84 KCNMA1 (0.60) KCNMA1ALDH1A1SERPINE1KDM4ELMNA
SCHEMBL1307027 0.84 PTPRC (0.59) KCNMA1ALDH1A1KDM4ETP53CA12
SCHEMBL1309941 0.84 SERPINE1 (0.65) ALDH1A1SERPINE1KDM4EHSD17B10PPARG
SCHEMBL8252530 0.83 ALDH1A1 (0.72) ALDH1A1KDM4EHSD17B10AKR1C3AKR1C2
SCHEMBL1307640 0.83 ALDH1A1 (0.60) ALDH1A1KDM4EAKR1C4AKR1C3AKR1C2
SCHEMBL1308303 0.83 TP53 (0.78) ALDH1A1SERPINE1KDM4EHSD17B10PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 KCNMA1 2149/4885ALDH1A1 33/4885SERPINE1 859/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 KCNMA1 975/4885ALDH1A1 63/4885SERPINE1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.